NDASUBCUTANEOUSSOLUTION
Approved
Jul 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LYMPHAZURIN (isosulfan blue) by Medtronic is 12. First approved in 1981.
Drug data last refreshed 10h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lymphazurin (isosulfan blue) is a diagnostic dye administered subcutaneously that binds to serum proteins and is taken up by lymphatic vessels, allowing visualization and delineation of the lymphatic system. It is used intraoperatively to identify lymph nodes and lymphatic drainage patterns during surgical procedures. The drug has been approved since 1981 and remains a surgical visualization standard.
LOE Approaching
This mature diagnostic product is approaching loss of exclusivity, signaling smaller commercial teams focused on manufacturing efficiency and defensive positioning against generic entry.
Mechanism of Action
12.2 Pharmacodynamics Following subcutaneous administration, isosulfan blue injection 1% binds to serum proteins and is picked up by the lymphatic vessels. Thus, the lymphatic vessels are delineated by the blue dye. 12.3 Pharmacokinetics Up to 10% of the subcutaneously administered dose of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Over 1,000 linked jobs span commercial, manufacturing, and operations roles, reflecting Medtronic's broad portfolio integration. Careers tied to Lymphazurin are trending toward supply chain, manufacturing efficiency, and field specialization rather than brand growth or innovation.
Sr. Product Specialist
Worked on LYMPHAZURIN at Medtronic? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.